MULTIDISCIPLINARY APPROACH Program.pdf · Fadi Nasr, MD Members Hanane Yassine, MD Mohamad Haidar,...

MULTIDISCIPLINARY APPROACH

Lebanese Society of Medical Oncology (LSMO)National Forum

April 11-13, 2019 | Phoenicia Hotel - Beirut, Lebanon


in collaboration with:


Lebanese Societyof MedicalOncology (LSMO)National Forum

16th

ZYTIGA® as first-line therapy in mCRPC and mHSPC delivers remarkable overall survival benefits without compromising quality of life, so your patients can stay active for longer.

FIRST NOVEL HORMONAL AGENT IN mCRPC*1

4.4 months median life extension vs prednisone alone in post-ADT (HR 0.81; 95% CI 0.70–0.93; P=0.0033)**2

4.6 months median life extension in post-chemotherapy patients (HR 0.74; 95% CI 0.64–0.86; P<0.0001)3

FIRST IN NEWLY DIAGNOSED HIGH-RISK mHSPC*1 Superior median overall survival vs ADT alone (HR 0.62; 95% CI 0.51–0.76; P<0.001)†4

SINCE 2011

FOR MAXIMUM IMPACT, USE ZYTIGA® PLUS PREDNISONE FIRST-LINE IN mCRPC AND mHSPC

Time for life

mCRPC=metastatic castration-resistant prostate cancer; mHSPC=metastatic hormone-sensitive prostate cancer; ADT=androgen deprivation therapy * ZYTIGA® approved for mCRPC post-chemotherapy in September 2011, mCRPC post-ADT in December 2012 and for newly diagnosed high-risk mHSPC in November 2017 ** Asymptomatic or mildly symptomatic patients with mCRPC post-ADT † Median time not reached for ZYTIGA® group




Welcome Letter

On behalf of the LSMO Organizing Committee, It gives me great pleasure to invite you all to participate in the “16th Lebanese Society of Medical Oncology National Forum LSMO” which will be held from 11-13 April 2019 at Phoenicia Hotel in Beirut Lebanon.

The objective of this unique conference is to promote the highest standards of healthcare in the management and support of patients with cancer. The program aims at equipping healthcare professionals with knowledge about recent developments, advance the effectiveness of healthcare practice and delivery and increase the quality of patient care.

The congress will provide both a forum for exchange on cutting-edge scientific and clinical information and will facilitate interactions among physicians, researchers, scientists, clinicians and other healthcare professionals from around the world to navigate the various challenges faced in further refining the health outcomes of patients suffering from cancer.

The scientific program contains a series of high-profile plenary presentations, symposia and concurrent sessions. Our aim is to bridge gaps and pave the future by hosting several international speakers from North America, Europe and the region who will be giving lectures on the recent updates in primary care, share valuable scientific knowledge in oncology, ranging from diagnostic and therapeutic tools and techniques to cutting-edge research.

I sincerely hope that this conference will deliberate and discuss all the different facets of oncology and come up with recommendations that will lead to a better, healthier world. The LSMO congresses have been very successful & well attended congresses with outstanding scientific programs where we can ensure that the 16th Annual Congress will not be an exception. We will put together another milestone on the way to success, focusing on the most important instrument to further improve our society: multiplying knowledge by sharing it with each other.I am convinced, the program will provide you with new information, better knowledge in oncology, provide ideas on how to improve your research and results and it will be a stimulus to further harmonize our medical standards and to successfully compete with our neighboring disciplines. Looking forward to a successful and fruitful congress and hoping to see you all there!

Nizar Bitar, MDLSMO President




Scientific Committee PresidentRoger Khater, MD

Past PresidentJoseph Makdessi, MD

TreasurerTherese Abou Nasr, MD

PresidentNizar Bitar, MD

President ElectRoger Khater, MD

General SecretaryOussama Jradi, MD

LSMO PresidentNizar Bitar, MD

Ahmad Awada, MDJeffrey Gregg, MDPeter Niehoff, MDPeter Schmid, MDRuben Cabanillas, MD

Scientific Committee

Executive Board

Internation Faculty

Members

Ali Shamseddine, MDArafat Tfayli, MDFadi Nasr , MD

MembersHanane Yassine, MD Mohamad Haidar, MDNaji Amro, MD

Rita Murr , MDWalid Moukadem, MD

Hazem Assi, MD Jad Wakim, MD Joseph Kattan, MD

Joseph Makdessi, MDRita Murr , MD Therese Abou Nasr , MD

Sana Al Sukhun, MDShouki Bazarbachi, MDStephan Chia, MDSuayib Yalcin, MDYohann Loriot, MD




Thursday, April 11, 2019

08:00 Registration

09:00 - 09:45 Optimizing Management of Pre/Post Menopausal Women with HR+ve ABC PatientsNovartis Symposium

Stephen Chia

09:45 - 10:30 Current Practice and Opportunities in the Management of HR+/HER2- mBC: Optimizing the Role of CDK4/6 Inhibitors in Clinical PracticePfizer Symposium

Hadi Ghanem

10:30 - 10:50 Coffee Break

10:50 - 11:35 Are all CDK4/6i the same? How Abemaciclib was Designed to be Different Lilly Symposium

Hazem Assi

11:35 - 12:05 Opening Ceremony

12:05 - 12:50 Current Questions on Why, When and How to Treat Non-Metastatic Castration-Resistant Prostate CancerJanssen Symposium

Marwan GhosnMichel Jabbour

12:50 - 13:50 Lunch Break

13:50 - 14:50 General Session13:50 - 14:15 Sequence of Treatment in Advanced Neuroendocrine

TumorsAli Shamseddine

14:15 - 14:40 Role of Checkpoints Inhibitors in the Adjuvant and Neoadjuvant Settings of Solid Tumors

Ahmad Awada

14:40 - 15:25 Reshaping the Management Paradigm of ALK/ROS1 Positive Non-Small Cell Lung Cancer (NSCLC)Pfizer Symposium

Arafat Tfaili





Thursday, April 11, 2019

15:45 - 16:30 The Role of Denosumab for Prevention of Skeletal Related Complications in Multiple Myeloma

Georges Chahine

Denosumab for the Prevention of Skeletal-Related Events in Patients with Bone Metastasis fromSolid TumorsAmgen Symposium

Sana Al Sukhun

16:30 - 18:30 Breast Session16:30 - 16:50 Genomic Expression Profiling and Selection of

Adjuvant Systemic Therapy in Early Breast Cancer Stephen Chia

16:50 - 17:10 Optimizing Adjuvant Therapy Decisions for HER2-Positive Early Breast Cancer

Nagi Saghir

17:10 - 17:30 Neoadjuvant Treatment in Primary Operable Breast Cancer: A More Individualized Approach to Systemic Therapies

Stephen Chia

17:30 - 17:50 Beyond HER2 and CDK4/6 Agents in Advanced Breast Cancers: Molecular Aberrations, New Targets and New Molecular Agents

Ahmad Awada

17:50 - 18:10 Targeting Immune Checkpoints in TNBC Hazem Assi18:10 - 18:30 Adjuvant Endocrine Therapy in Early HR-Positive

Breast Cancer, the Controversy of Duration Sana Al Sukhun

18:30 - 19:15 Role of Immunotherapy in mTNBC Roche Symposium

Peter Schmid




Friday, April 12, 2019

08:30 - 10:10 Lung Cancer08:30 - 08:55 Local Ablation Techniques in Early Stage NSCLC Nadim Muallem08:55 - 09:20 Immunotherapy in Non-Mutation Driven Advanced NSCLC Fadi Karak09:20 - 09:45 Advances in the Management of SCLC Ghazi Nsouli09:45 - 10:10 Approach to Patients with EGFR or ALK Mutated NSCLC Arafat Tfayli10:10 - 10:35 Mesothelioma: New Treatment Options Therese Abi Nasr


10:55 - 11:40 From Theory to Clinical Practice:Hallmarks of Immunotherapy CombinationsBMS Symposium

Sally Tamraz

11:40 - 12:40 Head & Neck11:40 - 12:00 Immunotherapy in Head and Neck Cancers Hadi Ghanem12:00 - 12:20 Approach to Patients with Iodine-Refractory Thyroid Cancer Marwan Ghosn12:20 - 12:40 Chemotherapy/Radiation vs. Cetuximab/Radiation Bassem Youssef

12:40 - 13:25 Pembrolizumab, Redefining the Standard of Care inMetastatic Non-Small Cell Lung CancerMSD Symposium

Ziad Salem


14:25 - 15:25 Cancers in Young Adults14:25 - 14:45 Bone Sarcoma Treatment in 2020: Current Advances Raya Saab14:45 - 15:05 Surgery for Bone Sarcomas:

Tumor Control and Functional Outcome Johnny Abdel Nour

15:05 - 15:25 Role of Radiation Therapy in Bone Sarcomas Caroline Jabbour




Friday, April 12, 2019

15:25 - 16:10 Implementing a Treatment Strategy in ManagingGastric and GEJ Cancer Eli Lilly Symposium

Ali Shamseddine


16:30 - 17:15 Looking Beyond Second-Line Treatment in Metastatic Colorectal CancerServier Symposium

Joseph KattanFadi Nasr

17:15 - 18:15 GI Session17:15 - 17:35 Recent Management of Advanced Cholangiocarcinoma Shouki Bazarbashi17:35 - 17:55 Adjuvant and Neoadjuvant Treatment in Gastric Cancer Suayib Yalcin17:55 - 18:15 Is Total Neoadjuvant Therapy is Becoming the Standard

of Care for Locally Advanced Rectal Cancer Ali Shamseddine

18:15 - 19:00 Pancreatic Session; Management of Resectable Pancreatic Cancer

18:15 - 18:30 The role Of Hepatobiliary Surgery on Outcome Claude Tayyar18:30 - 18:45 Adjuvant and Neoadjuvant Therapy in Pancreatic

Cancer Fadi Farhat

18:45 - 19:00 Impact of Radiation Therapy on Survival in PancreaticCancer

Yousef Zaidan

19:00 - 20:00 Unlocking the Potential in Precision Medicine Roche Launching Symposium

Ruben CabanillasJeffrey Gregg




In advanced gastric/GEJ adenocarcinomaAdding CYRAMZA to paclitaxel significantly increased OS vs paclitaxel alone1

you’ve gotI need everything

I don’t want a

fairy tale

CYRAMZA Summary of Product Characteristics:CYRAMZA® is a human vascular endothelial growth factor receptor 2 Antagonist indicated • as a single agent or in combination with paclitaxel, for treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. • in combination with docetaxel, for treatment of metastatic nonsmall cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA.• in combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. DOSE AND ADMINISTRATION: For intravenous infusion only. Do not administer as an intravenous push or bolus. Gastric Cancer• The recommended dose of CYRAMZA either as a single agent or in combination with weekly paclitaxel is 8 mg/kg every 2 weeks. Non-Small Cell Lung Cancer• Administer CYRAMZA at 10 mg/kg intravenously on day 1 of a 21-day cycle prior to docetaxel infusion. Colorectal Cancer • Administer CYRAMZA at 8 mg/kg intravenously every 2 weeks, prior to FOLFIRI administration. DOSAGE FORMS AND STRENGTHS: Injection: 100 mg/10 mL (10 mg per mL) solution, single-dose vial and 500 mg/50 mL (10 mg per mL) solution, single-dose vial. CONTRAINDICATIONS None. WARNINGS AND PRECAUTIONS • Arterial Thromboembolic Events (ATEs): Serious, sometimes fatal ATEs have been reported in clinical trials. Discontinue CYRAMZA for severe ATEs.• Hypertension: Monitor blood pressure and treat hypertension. Temporarily suspend CYRAMZA for severe hypertension. Discontinue CYRAMZA for hypertension that cannot be medically controlled. • Infusion-Related Reactions: Monitor for signs and symptoms during infusion.• Impaired Wound Healing: Withhold CYRAMZA prior to surgery.• Clinical Deterioration in Patients with Cirrhosis: New onset orworsening encephalopathy, ascites, or hepatorenal syndrome canoccur in patients with Child-Pugh B or C cirrhosis.• Reversible Posterior Leukoencephalopathy Syndrome: Discontinue CYRAMZA.• Proteinuria Including Nephrotic Syndrome: Monitor proteinuria. Interrupt CYRAMZA for urine protein levels ≥2 g/24 hours. Permanently discontinue CYRAMZA for urine protein levels>3 g/24 hours or for nephrotic syndrome. • Thyroid Dysfunction: Monitor thyroid function during treatment with CYRAMZA. • Embryofetal Risk: Can cause fetal harm. ADVERSE REACTIONS • The most common adverse reactions observed in single-agent CYRAMZA-treated patients at a rate of ≥10% and ≥2% higher than placebo were hypertension and diarrhea. • The most common adverse reactions observed in patients treated with CYRAMZA plus paclitaxel at a rate of ≥30% and ≥2% higher than placebo plus paclitaxel were fatigue, neutropenia, diarrhea, and epistaxis.• The most common adverse reactions observed in patients treatedwith CYRAMZA plus docetaxel at a rate of ≥30% and ≥2% higher than placebo plus docetaxel were neutropenia, fatigue/asthenia, and stomatitis/mucosal inflammation. • The most common adverse reactions observed in patients treated with CYRAMZA plus FOLFIRI at a rate of ≥30% and ≥2% higher than placebo plus FOLFIRI were diarrhea, neutropenia, decreased appetite, epistaxis, and stomatitis.

For further information about Lilly and Lilly products please contact us on the below address:Lebanon: Jisr el Wati, Sin El Fil, Fouad Ammoun Street, Plot #2252, 4th & 5th Floors, POB: 55-158Tel: (961) 1 504 700, Fax: (961) 1 504 701

For adverse events and safety reporting, please send an email to the following email address : [email protected].

PP-R

B-LB

-001

1

40 %40.1% (34.7, 45.5)

(n=330)In the placebo + paclitaxel arm

n=335), OS rate was 30.2%(25.1, 35.3) at 1 year.

1-yearOS rate

0 2 4 6 8 10 12 14 16 18 20 22 24 26 28

OS

PR

OB

AB

ILIT

Y

TIME FROM RANDOMIZATION (MONTHS)

CYRAMZA+ paclitaxel

(n=330)

Placebo+ paclitaxel(n=335)

9.6MONTHS(8.5, 10.8)

7.4MONTHS

(6.3, 8.4)

1.0

0.8

0.6

0.4

0.2

0.0

CYRAMZA+ paclitaxel

Placebo+ paclitaxel

330 308 267 228 185 148 116 78 60 41 24 13 6 1 0

335 294 241 180 143 109 81 64 47 30 22 13 5 2 0

NUMBER AT RISK

CYRAMZA + paclitaxel

Placebo+ paclitaxel

CI=confidence interval; GEJ=gastroesophageal junction; HR=hazard ratio; OS=overall survival. References: 1. Wilke H, Muro K, Van Cutsem E, et al; for the RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224-1235.




Saturday, April 13, 2019

08:15 - 09:00 Extend the Possibilities for Multiple Myeloma with NinlaroTakeda Symposium

Colette Hanna

09:00 - 09:45 The Promise of Immunotherapy in Melanoma BMS Symposium

TBA

09:45 - 10:45 Prostate Session09:45 - 10:05 The Paradigm Shift in Metastatic Hormone-Sensitive

Prostate CancerYohann Loriot

10:05 - 10:25 Nonsurgical Treatment of Localised Prostate Cancer Peter Niehoff10:25 - 10:45 PSA Rising in Non-Metastatic Castration Resistant

Prostate CancerElie Nemr

10:45 - 10:55 TBALecture Sponsored by Abbvie

TBA


11:25 - 12:10 mCRPC Management: Clinical Cases Discussion from a Multidisciplinary PerspectiveAstellas Symposium

Elie Nemr Deborah Mukherji

12:10 - 13:10 Bladder Session12:10 - 12:30 Immunotherapy in Early Stages Bladder Cancer Joseph Kattan12:30 - 12:50 Nonsurgical Treatment in Localised Bladder Cancer Peter Niehoff12:50 - 13:10 The State of the Art in the Treatment of Advanced

Bladder CancerYohann Loriot


14:10 - 14:55 Maximizing Treatment Benefits in advanced Renal Cell CarcinomaBiologix Symposium

Ali Shamseddine

14:55 - 15:40 Role of Pembrolizumab in Metastatic UrothelialCarcinomaMSD Symposium

Ghazi Nsouli




Saturday, April 13, 2019

PARALLEL SESSION | NURSE SESSION CARTHAGE HALL

08:30 - 10:35 Improving Quality Care08:30 - 08:35 Introduction to the Session08:35 - 08:50 Establishment of A Nurse Navigator Program

in Oncology Setting Wafaa Skaf

08:50 - 09:05 Quality Care Monitoring for Oncology Patients Mariam El Sabae09:05 - 09:25 Optimizing Drug Safety In Oncology Settings:

Clinical Pharmacy PerspectiveAya Kabbani

09:25 - 09:40 Integrated Palliative Care Sarah Lattouf09:40 - 10:00 Palliation beyond the Traditional:

Reaching Out to Patients and Caregivers Antoine Finianos

10:00 - 10:15 Psychological Support to Cancer Patients Dina Mouzayen10:15 - 10:30 Benefits of Art Therapy in Managing Oncology Patients Linda Harris10:30 - 10:35 Wrap-Up Session


11:00 - 12:00 Pain Control11:00 - 11:20 Pain Pearls Janane Hanna11:20 - 11:40 Finding Peace Beyond the Pain:

The Total Pain ConceptRana Yamout

11:40 - 12:00 The Cancer Pain Management in Daily Practice Ghassan Mohanna




Notes

-------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------

Organized by: 4th Floor, Qubic CenterDaoud Ammoun StreetHorsh Tabet - Sin El FilP.O. Box: 90-361 BeirutTel: +961 1 510880/1/2/3 Mobile: +961 71 103123

[email protected] | www.infomedweb.com

LEBANON UAE

|DMCC Business CentreAlmas TowerJumeirah Lakes Dubai, United Arab EmiratesUnit No: 3820Mobile: +971 50 9110475

The Lebanese Society of Medical Oncology (LSMO)would like to thank the following companies

for their contribution to the success of its annual congress

Improving lives since 1896.

A tradition of advancing science and medicine. Then, now and in the future.

NOW APPROVED FOR THE FIRST LINE TREATMENT OF PATIENTS WITH aRCC *1,2

®

* intermediate- or poor-risk aRCC patients

HIGHLIGHTS OF PRESCRIBING INFORMATION1

These highlights do not include all the information needed to use OPDIVO® safely and e�ectively. See full prescribing information for OPDIVO®.OPDIVO® (Nivolumab) injection, for intravenous use. Initial U.S. Approval: 2014INDICATIONS AND USAGE OPDIVO® is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of: Patients with BRAF V600 wild-type unresectable or metastatic melanoma as a single agent; with BRAF V600 mutation-positive unresectable or metastatic melanoma as a single agent;a with unresectable or metastatic melanoma, in combination with ipilimumab;a with melanoma with lymph node involvement or metastatic disease who have undergone complete resection, in the adjuvant setting. Patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy, with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO®. Patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy; with intermediate or poor risk, previously untreated advanced renal cell carcinoma, in combination with ipilimumab. Adult patients with classical Hodgkin lymphoma that has relapsed or progressed after: b autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin; or 3 or more lines of systemic therapy that includes autologous HSCT. Patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. Patients with locally advanced or metastatic urothelial carcinoma who: b have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.b Patients with hepatocellular carcinoma who have been previously treated with sorafenib.a DOSAGE AND ADMINISTRATION Administer as an intravenous infusion over 30 minutes. Unresectable or metastatic melanoma: OPDIVO® 240 mg every 2 weeks or 480 mg every 4 weeks. OPDIVO® with ipilimumab: OPDIVO® 1 mg/kg, followed by ipilimumab on the same day, every 3 weeks for 4 doses, then OPDIVO® 240 mg every 2 weeks or 480 mg every 4 weeks. Adjuvant treatment of melanoma: OPDIVO® 240 mg every 2 weeks or 480 mg every 4 weeks. Metastatic non-small cell lung cancer: OPDIVO® 240 mg every 2 weeks or 480 mg every 4 weeks. Advanced renal cell carcinoma: OPDIVO® 240 mg every 2 weeks or 480 mg every 4 weeks. OPDIVO® with ipilimumab: OPDIVO® 3 mg/kg followed by ipilimumab 1 mg/kg on the same day every 3 weeks for 4 doses, then OPDIVO® 240 mg every 2 weeks or 480 mg every 4 weeks. Classical Hodgkin lymphoma: OPDIVO® 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Recurrent or metastatic squamous cell carcinoma of the head and neck: OPDIVO® 240mg every 2 weeks or 480 mg every 4 weeks. Locally advanced or metastatic urothelial carcinoma: OPDIVO® 240 mg every 2 weeks or 480 mg every 4 weeks. Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer: OPDIVO® 240 mg every 2 weeks. Hepatocellular carcinoma: OPDIVO® 240 mg every 2 weeks or 480 mg every 4 weeks. WARNINGS AND PRECAUTIONS Immune-mediated pneumonitis: Withhold for moderate and permanently discontinue for severe or life-threatening pneumonitis. Immune-mediated colitis: Withhold OPDIVO® when given as a single agent for moderate or severe and permanently discontinue for life-threatening colitis. Withhold OPDIVO® when given with ipilimumab for moderate and permanently discontinue for severe or life-threatening colitis. Immune-mediated hepatitis: Monitor for changes in liver function. Withhold for moderate and permanently discontinue for severe or life-threatening transaminase or total bilirubin elevation. Immune-mediated endocrinopathies: Withhold for moderate or severe and permanently discontinue for life-threatening hypophysitis. Withhold for moderate and permanently discontinue for severe or life-threatening adrenal insu�ciency. Monitor for changes in thyroid function. Initiate thyroid hormone replacement as needed. Monitor for hyperglycemia. Withhold for severe and permanently discontinue for life-threatening hyperglycemia. Immune-mediated nephritis and renal dysfunction: Monitor for changes in renal function. Withhold for moderate or severe and permanently discontinue for life-threatening serum creatinine elevation. Immune-mediated skin adverse reactions: Withhold for severe and permanently discontinue for life-threatening rash. Immune-mediated encephalitis: Monitor for changes in neurologic function. Withhold for new-onset moderate to severe neurological signs or symptoms and permanently discontinue for immune-mediated encephalitis. Infusion reactions: Discontinue OPDIVO® for severe and life-threatening infusion reactions. Interrupt or slow the rate of infusion in patients with mild or moderate infusion reactions. Complications of allogeneic HSCT after OPDIVO®: Monitor for hyperacute graft-versus-host-disease (GVHD), grade 3-4 acute GVHD, steroid-requiring febrile syndrome, hepatic veno-occlusive disease, and other immune-mediated adverse reactions. Transplant-related mortality has occurred. Embryo-fetal toxicity: Can cause fetal harm. Advise of potential risk to a fetus and use of e�ective contraception. ADVERSE REACTIONS Most common adverse reactions (≥20%) in patients were: OPDIVO® as a single agent: fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper respiratory tract infection, pyrexia, headache, and abdominal pain. OPDIVO® with ipilimumab for melanoma: fatigue, rash, diarrhea, nausea, pyrexia, vomiting, and dyspnea. OPDIVO® with ipilimumab for renal cell carcinoma: fatigue, rash, diarrhea, musculoskeletal pain, pruritus, nausea, cough, pyrexia, arthralgia, and decreased appetite. USE IN SPECIFIC POPULATIONS Lactation: Discontinue breastfeeding.For any additional information or adverse events reporting, please contact Bristol-Myers Squibb Medical Information on http://www.globalbmsmedinfo.coma This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. b This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.aRCC=advanced renal cell carcinoma

OPDIVO® is indicated for the treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma, in combination with Ipilimumab1

Bristol-Myers SquibbLaboratory Complex

Dubai Science ParkP.O. Box: 454409, Dubai, UAE

Tel: +971-4-45021001506AE18PR04170-01

References:1. OPDIVO® (Nivolumab) US PI, April 2018 . 2. Motzer RJ, Tannir NM, McDermott DF, et al; Checkmate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;37B(14): 1277-1290.

MULTIDISCIPLINARY APPROACH Program.pdf · Fadi Nasr, MD Members Hanane Yassine, MD Mohamad Haidar,...

Documents

Transcript of MULTIDISCIPLINARY APPROACH Program.pdf · Fadi Nasr, MD Members Hanane Yassine, MD Mohamad Haidar,...